Table 2.
Clinical characteristics of patients treated with HMAs
| Cohesin mutant (n = 93) | Cohesin WT (n = 627) | P | |
|---|---|---|---|
| Patients treated with HMAs and response assessed | 16 | 124 | |
| Median age at start of therapy (y) | 71 | 69 | .98 |
| Median IPSS score at diagnosis | 1.5 | 1 | .7 |
| Cytogenetics at treatment | |||
| Normal | 8 | 53 | .79 |
| Abnormal karyotype | 8 | 67 | |
| Complex karyotype | 2 | 28 | .52 |
| −5/del(5q) | 1 | 19 | .46 |
| −7/del(7q) | 0 | 27 | .08 |
| Trisomy 8 | 3 | 8 | .22 |
| −20/del(20q) | 0 | 16 | .08 |
| Diagnosis at treatment | |||
| Low-risk MDS | 1 | 38 | .04 |
| High-risk MDS | 7 | 38 | .39 |
| sAML | 6 | 20 | .07 |
| MDS/MPN | 2 | 24 | .76 |
| MPN | 0 | 2 | 1 |
| pAML | 0 | 2 | 1 |
| Types of response per IWG criteria | |||
| Responder (CR, PR, and HI-E) | 13 | 59 | .02 |
| Nonresponder (SD and failure) | 3 | 65 | |
| Other somatic mutations | |||
| TET2 | 3 | 15 | .43 |
| TP53 | 0 | 5 | 1 |
| ASXL1 | 5 | 16 | .06 |
| DNMT3A | 1 | 14 | 1 |
| RUNX1 | 5 | 12 | .02 |
| IDH1 and IDH2 | 3 | 3 | .02 |
CR, complete remission; HI-E, hematologic improvement (erythroid); IWG, International Working Group; PR, partial remission; SD, stable disease.